Efficacy, safety, and immunogenicity of recombinant insulin aspart in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study

Background and purpose: To compare the efficacy, safety, and immunogenicity of recombinant insulin aspart 100 U/mL manufactured by BioGenomics Limited (BGL-ASP) with innovator NovoRapid[sup.®] in type 2 diabetes mellitus patients (T2 DM). Experimental approach: This was a multicenter, open-label, ra...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Research in pharmaceutical sciences 2024-09, Vol.19 (5), p.489
Hauptverfasser: Dongre, Sneha A, Kulkarni, Gauri A, Mishra, Akshay, Deshmane, Rutuja B, Sonar, Nameeta, Yashi, Kanica, Thapa, Damodar, Ghade, Nikhil, Kadoo, Sachin M, Krishnan, Archana R, Sonar, Sanjay M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page 489
container_title Research in pharmaceutical sciences
container_volume 19
creator Dongre, Sneha A
Kulkarni, Gauri A
Mishra, Akshay
Deshmane, Rutuja B
Sonar, Nameeta
Yashi, Kanica
Thapa, Damodar
Ghade, Nikhil
Kadoo, Sachin M
Krishnan, Archana R
Sonar, Sanjay M
description Background and purpose: To compare the efficacy, safety, and immunogenicity of recombinant insulin aspart 100 U/mL manufactured by BioGenomics Limited (BGL-ASP) with innovator NovoRapid[sup.®] in type 2 diabetes mellitus patients (T2 DM). Experimental approach: This was a multicenter, open-label, randomized, parallel-group study in T2 DM patients, on premix human insulin therapy ± oral anti-diabetics. Besides self-monitored plasma glucose, fasting and post-prandial plasma glucose (FPG and PPG) were tested at baseline, week 12, and week 24. Anti-insulin aspart antibodies measured immunogenicity at 12 and 24 weeks. Findings/Results: 160 patients out of 320 patients randomly received BGL-ASP and the remaining patients received NovoRapid[sup.®]. The changes in glycated hemoglobin (HbA1c) from baseline to weeks 12 and 24 for the BGL-ASP group were -0.8 ± 0.83 and -0.8 ± 0.81, respectively, while for the NovoRapid[sup.®]group was -0.8 ± 1.01 and -0.9 ± 0.89, respectively. Changes in FPG and PPG were comparable between the treatment groups after 12 weeks and 24 weeks. The incidence of detectable antibodies at baseline, weeks 12, and 24 were comparable between treatment groups. Eighteen (11.3%) patients in the BGL-ASP group and 23 (14.4%) in the NovoRapid®group reported adverse events. Conclusion and implications: BGL-ASP and NovoRapid[sup.®]were comparable and equally effective in lowering HbA1c, FPG, and PPG levels, with similar immunogenicity and safety profiles. Keywords: Biosimilar, Immunogenicity, Insulin aspart, NovoRapid.sup.®, Type 2 diabetes mellitus
doi_str_mv 10.4103/RPS.RPS_188_23
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A815704887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A815704887</galeid><sourcerecordid>A815704887</sourcerecordid><originalsourceid>FETCH-LOGICAL-g677-a1f0d3d5056c2fe2e619bb5030c1f94db814b446d2fe67159286cf70a9c262953</originalsourceid><addsrcrecordid>eNptjE1LxDAQhntQcFn36nnAa7sm6be3ZVk_YEHRvZc0mexGmrQ0KVJ_jT_ViB48OMPwMjPP-0bRFSXrjJL05uX5dR2moVXVsPQsWtAyzZM8LdhFtHLujYTKalbWbBF97pTSgos5BscV-qDcStDGTLY_otVC-xl6BSOK3rTacutBWzd12gJ3Ax-_V-By6ryDd-1P4OcBgYHUvEWPDgx2nfaTuwUOYwjvjf5AGUM_oE26AHUxmGDXAq3HMYbhxB0mKTg_yfkyOle8c7j61WV0uNsdtg_J_un-cbvZJ8eiLBNOFZGpzEleCKaQYUHrts1JSgRVdSbbimZtlhUyPIuS5jWrCqFKwmvBClbn6TK6_ok98g4bbVXvRy6MdqLZVDQvSVZVZaDW_1ChJRoteotKh_sfwxdLwXxt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy, safety, and immunogenicity of recombinant insulin aspart in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Medknow Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Dongre, Sneha A ; Kulkarni, Gauri A ; Mishra, Akshay ; Deshmane, Rutuja B ; Sonar, Nameeta ; Yashi, Kanica ; Thapa, Damodar ; Ghade, Nikhil ; Kadoo, Sachin M ; Krishnan, Archana R ; Sonar, Sanjay M</creator><creatorcontrib>Dongre, Sneha A ; Kulkarni, Gauri A ; Mishra, Akshay ; Deshmane, Rutuja B ; Sonar, Nameeta ; Yashi, Kanica ; Thapa, Damodar ; Ghade, Nikhil ; Kadoo, Sachin M ; Krishnan, Archana R ; Sonar, Sanjay M</creatorcontrib><description>Background and purpose: To compare the efficacy, safety, and immunogenicity of recombinant insulin aspart 100 U/mL manufactured by BioGenomics Limited (BGL-ASP) with innovator NovoRapid[sup.®] in type 2 diabetes mellitus patients (T2 DM). Experimental approach: This was a multicenter, open-label, randomized, parallel-group study in T2 DM patients, on premix human insulin therapy ± oral anti-diabetics. Besides self-monitored plasma glucose, fasting and post-prandial plasma glucose (FPG and PPG) were tested at baseline, week 12, and week 24. Anti-insulin aspart antibodies measured immunogenicity at 12 and 24 weeks. Findings/Results: 160 patients out of 320 patients randomly received BGL-ASP and the remaining patients received NovoRapid[sup.®]. The changes in glycated hemoglobin (HbA1c) from baseline to weeks 12 and 24 for the BGL-ASP group were -0.8 ± 0.83 and -0.8 ± 0.81, respectively, while for the NovoRapid[sup.®]group was -0.8 ± 1.01 and -0.9 ± 0.89, respectively. Changes in FPG and PPG were comparable between the treatment groups after 12 weeks and 24 weeks. The incidence of detectable antibodies at baseline, weeks 12, and 24 were comparable between treatment groups. Eighteen (11.3%) patients in the BGL-ASP group and 23 (14.4%) in the NovoRapid®group reported adverse events. Conclusion and implications: BGL-ASP and NovoRapid[sup.®]were comparable and equally effective in lowering HbA1c, FPG, and PPG levels, with similar immunogenicity and safety profiles. Keywords: Biosimilar, Immunogenicity, Insulin aspart, NovoRapid.sup.®, Type 2 diabetes mellitus</description><identifier>ISSN: 1735-5362</identifier><identifier>DOI: 10.4103/RPS.RPS_188_23</identifier><language>eng</language><publisher>Medknow Publications and Media Pvt. Ltd</publisher><subject>Adults ; Antibodies ; Care and treatment ; Complications and side effects ; Computers ; Dextrose ; Diabetes therapy ; Diabetics ; Evidence-based medicine ; Glucose ; Glycosylated hemoglobin ; Hypoglycemic agents ; Medical research ; Medicine, Experimental ; Pharmaceutical industry ; Services ; Type 2 diabetes ; Viral antibodies</subject><ispartof>Research in pharmaceutical sciences, 2024-09, Vol.19 (5), p.489</ispartof><rights>COPYRIGHT 2024 Medknow Publications and Media Pvt. Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Dongre, Sneha A</creatorcontrib><creatorcontrib>Kulkarni, Gauri A</creatorcontrib><creatorcontrib>Mishra, Akshay</creatorcontrib><creatorcontrib>Deshmane, Rutuja B</creatorcontrib><creatorcontrib>Sonar, Nameeta</creatorcontrib><creatorcontrib>Yashi, Kanica</creatorcontrib><creatorcontrib>Thapa, Damodar</creatorcontrib><creatorcontrib>Ghade, Nikhil</creatorcontrib><creatorcontrib>Kadoo, Sachin M</creatorcontrib><creatorcontrib>Krishnan, Archana R</creatorcontrib><creatorcontrib>Sonar, Sanjay M</creatorcontrib><title>Efficacy, safety, and immunogenicity of recombinant insulin aspart in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study</title><title>Research in pharmaceutical sciences</title><description>Background and purpose: To compare the efficacy, safety, and immunogenicity of recombinant insulin aspart 100 U/mL manufactured by BioGenomics Limited (BGL-ASP) with innovator NovoRapid[sup.®] in type 2 diabetes mellitus patients (T2 DM). Experimental approach: This was a multicenter, open-label, randomized, parallel-group study in T2 DM patients, on premix human insulin therapy ± oral anti-diabetics. Besides self-monitored plasma glucose, fasting and post-prandial plasma glucose (FPG and PPG) were tested at baseline, week 12, and week 24. Anti-insulin aspart antibodies measured immunogenicity at 12 and 24 weeks. Findings/Results: 160 patients out of 320 patients randomly received BGL-ASP and the remaining patients received NovoRapid[sup.®]. The changes in glycated hemoglobin (HbA1c) from baseline to weeks 12 and 24 for the BGL-ASP group were -0.8 ± 0.83 and -0.8 ± 0.81, respectively, while for the NovoRapid[sup.®]group was -0.8 ± 1.01 and -0.9 ± 0.89, respectively. Changes in FPG and PPG were comparable between the treatment groups after 12 weeks and 24 weeks. The incidence of detectable antibodies at baseline, weeks 12, and 24 were comparable between treatment groups. Eighteen (11.3%) patients in the BGL-ASP group and 23 (14.4%) in the NovoRapid®group reported adverse events. Conclusion and implications: BGL-ASP and NovoRapid[sup.®]were comparable and equally effective in lowering HbA1c, FPG, and PPG levels, with similar immunogenicity and safety profiles. Keywords: Biosimilar, Immunogenicity, Insulin aspart, NovoRapid.sup.®, Type 2 diabetes mellitus</description><subject>Adults</subject><subject>Antibodies</subject><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>Computers</subject><subject>Dextrose</subject><subject>Diabetes therapy</subject><subject>Diabetics</subject><subject>Evidence-based medicine</subject><subject>Glucose</subject><subject>Glycosylated hemoglobin</subject><subject>Hypoglycemic agents</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Pharmaceutical industry</subject><subject>Services</subject><subject>Type 2 diabetes</subject><subject>Viral antibodies</subject><issn>1735-5362</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptjE1LxDAQhntQcFn36nnAa7sm6be3ZVk_YEHRvZc0mexGmrQ0KVJ_jT_ViB48OMPwMjPP-0bRFSXrjJL05uX5dR2moVXVsPQsWtAyzZM8LdhFtHLujYTKalbWbBF97pTSgos5BscV-qDcStDGTLY_otVC-xl6BSOK3rTacutBWzd12gJ3Ax-_V-By6ryDd-1P4OcBgYHUvEWPDgx2nfaTuwUOYwjvjf5AGUM_oE26AHUxmGDXAq3HMYbhxB0mKTg_yfkyOle8c7j61WV0uNsdtg_J_un-cbvZJ8eiLBNOFZGpzEleCKaQYUHrts1JSgRVdSbbimZtlhUyPIuS5jWrCqFKwmvBClbn6TK6_ok98g4bbVXvRy6MdqLZVDQvSVZVZaDW_1ChJRoteotKh_sfwxdLwXxt</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Dongre, Sneha A</creator><creator>Kulkarni, Gauri A</creator><creator>Mishra, Akshay</creator><creator>Deshmane, Rutuja B</creator><creator>Sonar, Nameeta</creator><creator>Yashi, Kanica</creator><creator>Thapa, Damodar</creator><creator>Ghade, Nikhil</creator><creator>Kadoo, Sachin M</creator><creator>Krishnan, Archana R</creator><creator>Sonar, Sanjay M</creator><general>Medknow Publications and Media Pvt. Ltd</general><scope/></search><sort><creationdate>20240901</creationdate><title>Efficacy, safety, and immunogenicity of recombinant insulin aspart in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study</title><author>Dongre, Sneha A ; Kulkarni, Gauri A ; Mishra, Akshay ; Deshmane, Rutuja B ; Sonar, Nameeta ; Yashi, Kanica ; Thapa, Damodar ; Ghade, Nikhil ; Kadoo, Sachin M ; Krishnan, Archana R ; Sonar, Sanjay M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g677-a1f0d3d5056c2fe2e619bb5030c1f94db814b446d2fe67159286cf70a9c262953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adults</topic><topic>Antibodies</topic><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>Computers</topic><topic>Dextrose</topic><topic>Diabetes therapy</topic><topic>Diabetics</topic><topic>Evidence-based medicine</topic><topic>Glucose</topic><topic>Glycosylated hemoglobin</topic><topic>Hypoglycemic agents</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Pharmaceutical industry</topic><topic>Services</topic><topic>Type 2 diabetes</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dongre, Sneha A</creatorcontrib><creatorcontrib>Kulkarni, Gauri A</creatorcontrib><creatorcontrib>Mishra, Akshay</creatorcontrib><creatorcontrib>Deshmane, Rutuja B</creatorcontrib><creatorcontrib>Sonar, Nameeta</creatorcontrib><creatorcontrib>Yashi, Kanica</creatorcontrib><creatorcontrib>Thapa, Damodar</creatorcontrib><creatorcontrib>Ghade, Nikhil</creatorcontrib><creatorcontrib>Kadoo, Sachin M</creatorcontrib><creatorcontrib>Krishnan, Archana R</creatorcontrib><creatorcontrib>Sonar, Sanjay M</creatorcontrib><jtitle>Research in pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dongre, Sneha A</au><au>Kulkarni, Gauri A</au><au>Mishra, Akshay</au><au>Deshmane, Rutuja B</au><au>Sonar, Nameeta</au><au>Yashi, Kanica</au><au>Thapa, Damodar</au><au>Ghade, Nikhil</au><au>Kadoo, Sachin M</au><au>Krishnan, Archana R</au><au>Sonar, Sanjay M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy, safety, and immunogenicity of recombinant insulin aspart in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study</atitle><jtitle>Research in pharmaceutical sciences</jtitle><date>2024-09-01</date><risdate>2024</risdate><volume>19</volume><issue>5</issue><spage>489</spage><pages>489-</pages><issn>1735-5362</issn><abstract>Background and purpose: To compare the efficacy, safety, and immunogenicity of recombinant insulin aspart 100 U/mL manufactured by BioGenomics Limited (BGL-ASP) with innovator NovoRapid[sup.®] in type 2 diabetes mellitus patients (T2 DM). Experimental approach: This was a multicenter, open-label, randomized, parallel-group study in T2 DM patients, on premix human insulin therapy ± oral anti-diabetics. Besides self-monitored plasma glucose, fasting and post-prandial plasma glucose (FPG and PPG) were tested at baseline, week 12, and week 24. Anti-insulin aspart antibodies measured immunogenicity at 12 and 24 weeks. Findings/Results: 160 patients out of 320 patients randomly received BGL-ASP and the remaining patients received NovoRapid[sup.®]. The changes in glycated hemoglobin (HbA1c) from baseline to weeks 12 and 24 for the BGL-ASP group were -0.8 ± 0.83 and -0.8 ± 0.81, respectively, while for the NovoRapid[sup.®]group was -0.8 ± 1.01 and -0.9 ± 0.89, respectively. Changes in FPG and PPG were comparable between the treatment groups after 12 weeks and 24 weeks. The incidence of detectable antibodies at baseline, weeks 12, and 24 were comparable between treatment groups. Eighteen (11.3%) patients in the BGL-ASP group and 23 (14.4%) in the NovoRapid®group reported adverse events. Conclusion and implications: BGL-ASP and NovoRapid[sup.®]were comparable and equally effective in lowering HbA1c, FPG, and PPG levels, with similar immunogenicity and safety profiles. Keywords: Biosimilar, Immunogenicity, Insulin aspart, NovoRapid.sup.®, Type 2 diabetes mellitus</abstract><pub>Medknow Publications and Media Pvt. Ltd</pub><doi>10.4103/RPS.RPS_188_23</doi></addata></record>
fulltext fulltext
identifier ISSN: 1735-5362
ispartof Research in pharmaceutical sciences, 2024-09, Vol.19 (5), p.489
issn 1735-5362
language eng
recordid cdi_gale_infotracmisc_A815704887
source DOAJ Directory of Open Access Journals; PubMed Central Open Access; Medknow Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Adults
Antibodies
Care and treatment
Complications and side effects
Computers
Dextrose
Diabetes therapy
Diabetics
Evidence-based medicine
Glucose
Glycosylated hemoglobin
Hypoglycemic agents
Medical research
Medicine, Experimental
Pharmaceutical industry
Services
Type 2 diabetes
Viral antibodies
title Efficacy, safety, and immunogenicity of recombinant insulin aspart in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A59%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy,%20safety,%20and%20immunogenicity%20of%20recombinant%20insulin%20aspart%20in%20adults%20with%20type%202%20diabetes%20mellitus:%20a%20randomized,%20open-label,%20multicenter,%20phase-3%20study&rft.jtitle=Research%20in%20pharmaceutical%20sciences&rft.au=Dongre,%20Sneha%20A&rft.date=2024-09-01&rft.volume=19&rft.issue=5&rft.spage=489&rft.pages=489-&rft.issn=1735-5362&rft_id=info:doi/10.4103/RPS.RPS_188_23&rft_dat=%3Cgale%3EA815704887%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A815704887&rfr_iscdi=true